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for Stable Coronary Artery Disease
Demosthenes G. Katritsis, MD, PHD,* Bernhard Meier, MD†
Athens, Greece; and Bern, Switzerland
Patients with significant coronary artery stenoses are at increased risk of future cardiac events. However, in the
absence of acute coronary syndrome or recent myocardial infarction and residual ischemia, elective percutane-
ous coronary intervention has not been shown to improve prognosis. Possible explanations for this might be the
limited follow-up time adopted by most randomized trials comparing percutaneous coronary intervention with
medical therapy, limited number of patients with proven ischemia enrolled in these trials, and adoption of com-
plex, elaborate techniques that have not proved their usefulness. Published evidence identifies certain indica-
tions for percutaneous coronary intervention in patients with stable coronary lesions: demonstration of signifi-
cant inducible ischemia, particularly in the context of a recent myocardial infarction; detection of unequivocally
reduced fractional flow reserve; and specific angiographic features of coronary stenoses. Operators should take
into account long-term consequences of adopted techniques rather than immediate angiographic results. We
review existing evidence and provide our recommendations in this setting. (J Am Coll Cardiol 2008;52:
889–93) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.0488
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fecent randomized trials (1,2) and meta-analyses (3–5)
ave argued against the clinical usefulness of percutaneous
oronary intervention (PCI) in patients with stable coronary
rtery disease. Although PCI undoubtedly relieves angina
nd reduces the need of medication, thus improving the
uality of life, there is no proof of effect on hard clinical
utcomes such as cardiac or total mortality. Indeed, in the
bsence of acute coronary syndrome (6) or recent myocardial
nfarction (MI) and residual ischemia (7), elective PCI has
ot been shown to improve prognosis and might even be
armful (3). However, patients with significant coronary
rtery stenoses are at increased risk of future cardiac events.
n longitudinal studies in patients with known or suspected
oronary artery disease, detection of ischemia predicts a
ignificantly higher overall mortality, cardiac death, or MI
8–10), even in the absence of angina (11), whereas normal
cintigraphy studies identify patients with a good prognosis
t a low risk for future cardiac events (10,12). Myocardial
schemia is an established cause of polymorphic ventricular
achycardia or fibrillation and sudden cardiac death (13–15).
he majority of sudden deaths due to ischemic heart disease
re not associated with an acute MI (16–18), but transient
cute ischemia is an important trigger, preceding 35% to
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ccepted May 26, 2008.0% of deaths due to a ventricular tachyarrhythmia (19–21).
ot unexpectedly, therefore, the extent of significant lesions
i.e., 50% diameter stenosis) on the coronary arteries has
een correlated with long-term mortality (22), and revascu-
arization, either by PCI or surgery, usually (23,24), al-
hough not invariably (25), confers a greater survival benefit
han medical therapy in patients with significant inducible
schemia.
Why then can we not document a reduction of cardiac
isks in the presence of stable but angiographically signifi-
ant coronary artery stenoses for PCI? Several plausible
xplanations can be offered.
ollow-Up Time
f we consider the randomized trials that have been studied
n the 2 most recent meta-analyses (3,4), the median
ollow-up was only 2 years. With the exemption of the
WISSI II (Swiss Interventional Study on Silent Ischemia
ype II) trial (10.2 years) (26), and the COURAGE
Clinical Outcomes Utilizing Revascularization and Ag-
ressive Drug Evaluation) trial (4.6 years) (1), patients were
ollowed up for just a few years. This time is probably
nadequate to show any significant effect on the natural
istory of coronary artery disease, an insidious condition
hat may take more than 10 years to demonstrate its harmful
onsequences. Hence, in light of the inadequate duration of
ollow-up, the lack of proof of efficacy is likely not the proof
f lack of efficacy.
r
o
S
t
e
c
a
b
r
i
9
c
m
n
s
d
e
o
r
p
d
i
l
a
l
d
t
l
M
m
s
c
i
c
t
f
a
u
f
e
a
w
l
d
c
p
n
a
nd
om
iz
ed
S
tu
di
es
of
M
T
V
er
su
s
P
C
I
in
P
at
ie
nt
s
W
it
h
D
oc
um
en
te
d
Is
ch
em
ia
ab
le
1
R
an
do
m
iz
ed
S
tu
di
es
of
M
T
V
er
su
s
P
C
I
in
P
at
ie
nt
s
W
it
h
D
oc
um
en
te
d
Is
ch
em
ia
S
tu
dy
M
T/
P
C
I,
n
P
ri
or
M
I,
(%
)
N
o
A
ng
in
a,
(%
)
Is
ch
em
ia
Fo
llo
w
-U
p,
(y
rs
)
S
te
nt
s
M
T
D
ea
th
,
n
P
C
I
D
ea
th
,
n
M
T
C
ar
di
ac
D
ea
th
,
n
P
C
I
C
ar
di
ac
D
ea
th
,
n
M
T
N
FM
I,
n
P
C
I
N
FM
I,
n
C
M
E
(1
ve
ss
el
),
H
ar
tig
an
et
al
.(
2
9
)
1
0
7
/1
0
5
3
1
9
ET
T
or
re
ce
nt
M
I
3
N
o
1
5
1
6
N
D
N
D
7
6
C
M
E
(2
ve
ss
el
s)
,
Fo
lla
nd
et
al
.(
3
0
)
5
0
/5
1
4
1
1
8
ET
T
or
re
ce
nt
M
I
5
N
o
1
0
9
N
D
N
D
6
6
ak
ik
et
al
.(
3
1
)
2
2
/1
9
1
0
0
N
D
A
de
no
si
ne
S
P
EC
T
1
1
4
%
1
1
1
1
0
2
am
br
ec
ht
et
al
.(
3
2
)
5
1
/5
0
4
6
0
Tc
9
9
sc
in
tig
ra
ph
y
1
1
0
0
%
0
0
0
0
0
1
O
U
R
A
G
E,
B
od
en
et
al
.(
1
)
1
,1
3
8
/1
,1
4
9
3
9
1
3
9
5
%
in
du
ci
bl
e
is
ch
em
ia
*
4
.6
Fe
w
7
4
6
8
2
5
2
3
1
2
8
1
4
3
W
IS
S
II
I,
K
as
tr
at
i(
7
)
1
0
5
/9
6
1
0
0
1
0
0
S
ci
nt
ig
ra
ph
y
or
S
E
or
st
re
ss
R
N
1
0
.2
N
o
2
2
6
2
2
3
4
0
1
1
rc
is
e-
or
va
so
di
la
to
r
st
re
ss
-in
du
ce
d
is
ch
em
ia
.
T

ex
er
ci
se
tr
ea
dm
ill
te
st
;M
I
m
yo
ca
rd
ia
li
nf
ar
ct
io
n;
M
T

m
ed
ic
al
th
er
ap
y;
N
D

no
da
ta
;N
FM
I
no
nf
at
al
m
yo
ca
rd
ia
li
nf
ar
ct
io
n,
P
C
I
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n;
R
N

ra
di
on
uc
lid
e
an
gi
og
ra
ph
y;
S
E

st
re
ss
ec
ho
ca
rd
io
gr
ap
hy
;S
P
EC
T

si
ng
le
-p
ho
to
n
ss
io
n
co
m
pu
te
d
to
m
og
ra
ph
y.
890 Katritsis and Meier JACC Vol. 52, No. 11, 2008
PCI in Stable CAD September 9, 2008:889–93Presence of Ischemia
Patients enrolled in studies com-
paring medical therapy with PCI
did not represent a homogeneous
cohort. For example, of the 2,950
patients who were involved in a
ecent meta-analysis, only 455 patients enrolled in 4 out
f 10 studies had objectively detectable ischemia (3).
ubgroup analyses in this study produced no evidence
hat trials with definitive documentation of ischemia by
xercise test or scintigraphy had different risk ratios
ompared with trials where functional ischemia was not
s thoroughly documented. However, a possible survival
enefit was seen for PCI in trials of patients who had a
elatively recent MI (risk ratio: 0.40, 95% confidence
nterval: 0.17 to 0.95) (3). In the COURAGE trial (1),
5% of patients had documented ischemia total and
ardiac mortality was not statistically different between
edical therapy and PCI groups. Yet in the COURAGE
uclear substudy (27), more PCI patients exhibited
ignificant ischemia reduction and had lower risk for
eath or MI, particularly if baseline ischemia was mod-
rate to severe. In the SWISSI II trial (26), a clear benefit
f PCI was also demonstrated with an unequivocal
eduction of cardiac and total mortality in patients with
roven silent ischemia. The ACIP (Asymptomatic Car-
iac Ischemia Pilot) study (24) found improvements in
schemia and improved clinical outcomes with revascu-
arization, primarily with coronary artery bypass grafting,
lthough the numbers of major clinical events were
imited. The DANAMI (Danish trial in Acute Myocar-
ial Infarction) trial (28) found similar mortality rates in
he 2 arms and a modest reduction in MI with revascu-
arization over 2.4 years of follow-up in survivors of acute
I, and the benefit pertained to patients with docu-
ented ischemia. If we consider randomized compari-
ons of PCI versus medical therapy in patients with
learly detected ischemia, there is also a clear trend for
mproved outcomes with PCI by means of both total and
ardiac mortality (Table 1) (1,7,29 –32). Notably, the
rend seems to be driven by studies with the longer
ollow-up time. The symptomatic status of the patient is
lso important, particularly in the context of relative
ncertainty and lack of convergence between various tests
or the detection of ischemia. Imaging tests such as
xercise scintigraphy results do not correlate well with
ngiographic findings, both in patients with (33) and
ithout angina (34) and they may not identify the culprit
esion(s) with certainty in the presence of multivessel
isease (35). Fractional flow reserve shows modest con-
ordance with imaging tests such as perfusion scintigra-
hy and dobutamine stress echocardiography (36). Thus,
o single test is a valid substitute for clinical judgment
Abbreviations
and Acronyms
MI  myocardial infarction
PCI  percutaneous
coronary interventionnd individualized care for each of our patients. Ra T A A D H C S *E
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September 9, 2008:889–93 PCI in Stable CADngiographic Characteristics of Stenoses
vidence of ischemia sought before intervention in stable
atients is the ideal background of ad hoc angioplasty. Short
f it, several angiographic features are to be considered by
he interventionist for sensible decisions. Significant discor-
ance between quantitative coronary angiography and frac-
ional flow reserve has been demonstrated for lesions with
0% to 70% diameter stenoses (35). Thus, there is always
ncertainty about borderline stenoses that generally do well
ith medical therapy alone. Subtotal occlusions of vessels
upplying the noninfarcted myocardium; stenoses greater
han 90% that by definition represent vulnerable plaques
37); significant, complex lesions that are prone to develop
otal occlusions (38); and stenoses with unequivocally re-
uced fractional flow reserve (0.75%) (39,40), undoubt-
dly, represent optimal targets for PCI. Although MIs often
ccur at sites of mild-to-moderate stenoses (41,42), post-
ortem examinations have demonstrated that ruptured
laques leading to acute coronary syndrome more likely
ccur within the segment of significant stenoses (43–45).
here are good arguments that these cases should not
eceive medical therapy alone. We also believe that less
evere lesions (i.e., 90% diameter stenosis) should not be
utomatically excluded from PCI, particularly when offered
d hoc during the session of diagnostic angiography, judi-
iously assessing the global situation of the patient. Ran-
omized data to support our view are still lacking. The
-year follow-up of a respective trial failed to show a benefit
n hard end points of PCI over medical treatment (46).
ndirectly, this signifies that having performed PCI when it
as handy (during the diagnostic coronary angiogram) was
ot harmful. Although both groups were doing well during
his limited follow-up, the problem can only be considered
olved in the group with PCI.
Notwithstanding, the adoption of strict indications for
CI as opposed to the subjectivity of nonscientific ap-
roaches such as the so-called occulostenotic reflex applied
o every identified lesion is the basis of optimal clinical
utcome following PCI.
CI Techniques
urrent PCI techniques and approaches in general may also
e inappropriate at times. If anything, there is a trend for
ore cardiac deaths or MIs, in particular nonfatal MIs, in
atients who undergo PCI, with the point estimate suggest-
ng approximately a 30% increase in the relative risk of
onfatal MI with PCI (3). Thus, it might be that we negate
benefit offered by alleviation of ischemia through stenosis
ilation by an avoidably increased iatrogenic risk of intra-
rocedural or late MI. We tend to downplay procedure-
elated MIs by a threshold enzyme rise of at least 3 times the
pper limit of normal to define PCI-induced MI (47).
here has been evidence that myocardial necrosis has
rognostic significance regardless of its extent (48,49). The Ra T P C N *B
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PCI in Stable CAD September 9, 2008:889–93se of stents (particularly the drug-eluting types) is associ-
ted with an increased risk of late thrombosis, particularly
hen very long, overlapping, or side-branch stents are used
50). In the 3 randomized comparisons published so far,
ide-branch stenting, regardless of the deployed technique
dopted, was associated with an increased incidence of MI,
tent thrombosis, and target lesion revascularization (51–
3), not to mention irradiation doses and costs (Table 2).
evertheless, various techniques for both main vessel and
ide-branch stenting are routinely used by most in an effort
o achieve an ideal angiographic result. Brophy et al. (54)
ave elegantly shown that beyond a 20% to 40% rate of
tenting, there is no additional benefit to be expected over
lain balloon angioplasty.
Thus, published evidence identifies certain indications for
CI, and revascularization in general, in patients with stable
oronary lesions. A history of recent MI (3 months),
emonstration of significant inducible ischemia, detection
f unequivocally reduced fractional flow reserve, or the
resence of specific angiographic features of coronary ste-
oses are necessary to indicate PCI. Operators should take
nto account long-term consequences of adopted techniques
ather than immediate angiographic results. The art of
eeping things as simple as possible with the whole picture
nd the long-term outcome in the focus could not be more
alled for than in this setting.
eprint requests and correspondence: Dr. Demosthenes G. Katrit-
is, Department of Cardiology, Athens Euroclinic, 9 Athanassiadou
treet, Athens, Attica 11521, Greece. E-mail: dkatritsis@
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